AI-generated summary
The authors retrospectively reviewed 12 patients with systemic sclerosis who had 15 finger skin ulcers treated with blue light photobiomodulation (EmoLED) alongside debridement and standard care, comparing them with 8 control patients. They report faster healing, complete healing in 41.6% of cases, and no adverse events. The study was retrospective and preliminary, with a small sample and no randomization.
- Who or what was studied
- Patients with systemic sclerosis and finger skin ulcers: 12 treated with EmoLED and 8 controls
- Limits stated in the abstract
- The study was a small, retrospective, preliminary analysis with a control group that was not randomized and only 8 controls.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.